|
|
Article: Strong medicine: pharmaceutical giant Eli Lilly turns Brazil into a springboard for value-added products.(Eli Lilly and Co.'s Eli Lilly do Brasil' sales and earnings)
- Article from:
- Revista Latin Trade
- Article date:
- April 1, 2006
- Author:
CopyrightCOPYRIGHT 2006 Freedom Magazines, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The last two years have been good to U.S. pharmaceutical company Eli Lilly's Brazilian unit, Eli Lilly do Brasil. The drug maker grew more than any other drug company in Brazil. In 2004, Lilly revenues jumped 53% while the market average grew 22%.
Last year, total revenues hit US$150 million, doubling what it sold three years earlier. Such strong results made it possible for the company to make an announcement in July of last year that it achieved a goal originally set for this year: To be counted among the top 15 pharmaceutical laboratories in Brazil.
The president of Eli Lilly's Brazilian and Southern Cone operations, Philippe Prufer, turned the ...